Kersti Oselin

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Mary O’Brien, Luis Paz‐Ares, Sandrine Marréaud et al. · The Lancet Oncology · 2022 · 696 citations

Interim Analysis, Surgical Oncology, Oncology +8

MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males

Thomas Gerloff, Melanie Schaefer, Andreas Johne et al. · British Journal of Clinical Pharmacology · 2002 · 149 citations · Full text

Pharmacokinetics of Meropenem Determined by Microdialysis in the Peritoneal Fluid of Patients With Severe Peritonitis Associated With Septic Shock

Juri Karjagin, Sandrine Lefeuvre, Kersti Oselin et al. · Clinical Pharmacology & Therapeutics · 2007 · 73 citations

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

L. Paz-Ares, E O’Brien, M. Mauer et al. · Annals of Oncology · 2022 · 71 citations

Medicine, Clinical Trials, Adjuvant Chemotherapy +9

MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes

Kersti Oselin, Thomas Gerloff, P.M. Mrozikiewicz et al. · Fundamental and Clinical Pharmacology · 2003 · 67 citations